Overview

Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Status:
Recruiting
Trial end date:
2026-03-24
Target enrollment:
Participant gender:
Summary
Evaluate the safety and tolerability of AMG 509 in adult subjects and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).
Phase:
Phase 1
Details
Lead Sponsor:
Amgen
Treatments:
BB 1101
Dexamethasone
Dexamethasone acetate